Navigation Links
Genoptix, Inc. to Announce First Quarter 2010 Financial Results
Date:4/22/2010

CARLSBAD, Calif., April 22 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, announced today that it expects to report its financial results for the first quarter 2010 after closing of the NASDAQ Global Select Market on Thursday, May 6, 2010.

A conference call hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management will take place on the same day at 2:00pm PDT (5:00pm EDT) and will be webcast live on the Genoptix website.

To access the live conference call via phone, dial 866-730-5771 in the U.S. or Canada and 857-350-1595 for international callers. Please specify to the operator that you would like to join the "Genoptix First Quarter 2010 Earnings Conference Call." The participant code for the call is 91886738. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, May 13, 2010. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 86046951.

The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Thursday, June 3, 2010.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results
2. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
3. Cardica to Announce Fiscal 2010 Third Quarter Financial Results on Tuesday, May 4, 2010
4. Codexis, Inc. Announces Pricing of Initial Public Offering
5. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
6. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
7. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Robbins & Myers Announces Regular Quarterly Cash Dividend
11. EmSense Announces Release of Revolutionary EmBand 24(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):